Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns

Executive Summary

Alexion has only managed to convince NICE to recommend Strensiq for treatment in a limited patient population with pediatric-onset hypophosphatasia. The news is a step forward after NICE initially declined the drug altogether, but the new recommendations highlight the difficulties companies face when trying to justify high orphan drug prices.

Advertisement

Related Content

Q1 Earnings In Brief: Celgene, Alkermes, Novo Nordisk, Acorda, Alexion
Alexion Rare Disease Launches Off To Slow Start

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel